EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study

Oleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, Mario Mandalà, Mariia Kukushkina, Timothy Panella, Tibor Csőszi, Paola Gerletti, Mahgull Thakur, Anna Polli, Alessandra di Pietro, Dirk Schadendorf

European Journal of Cancer · 2024-12 · 213 · 115070

DOI: 10.1016/j.ejca.2024.115070 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024-12. Verfasst von Oleksandr Dudnichenko und 11 weiteren Autor:innen. Beteiligte Einrichtung: Kharkiv Regional Oncology Center, Kharkiv, Ukraine. Hauptthemen laut MEDLINE: Melanoma, Antineoplastic Combined Chemotherapy Protocols, Sulfonamides, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntineoplastic Combined Chemotherapy ProtocolsSulfonamidesProto-Oncogene Proteins B-rafCarbamatesAntibodies, Monoclonal, HumanizedBenzimidazolesHumansMaleFemaleMiddle AgedAgedAdultSkin NeoplasmsMutationAged, 80 and over

Stichwörter der Autor:innen

BRAF-mutantBinimetinibEncorafenibMelanomaPembrolizumab

Substanzen

binimetinibencorafenibpembrolizumabSulfonamidesProto-Oncogene Proteins B-rafCarbamatesAntibodies, Monoclonal, HumanizedBenzimidazolesBRAF protein, human

Autor:innen und Institutionen

  • Kharkiv Regional Oncology Center, Kharkiv, Ukraine.
  • Private Medical Institution Euromedservice, St. Petersburg, Russia.
  • Sarah Cannon Research Institute, Nashville, TN, USA.
  • Unit of Medical Oncology, University of Perugia, Perugia, Italy.
  • Department of Skin and Soft Tissue Tumors, National Cancer Institute, Kiev, Ukraine.
  • Department of Medicine, Division of Hematology & Oncology, University of Tennessee Medical Center, Knoxville, TN, USA.

Förderung

  • Pfizer

Zitieren

APA

Dudnichenko, O., Penkov, K., McKean, M., Mandalà, M., Kukushkina, M., Panella, T., Csőszi, T., Gerletti, P., Thakur, M., Polli, A., di Pietro, A., & Schadendorf, D. (2024). First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study. European Journal of Cancer, 213, 115070. https://doi.org/10.1016/j.ejca.2024.115070

Vancouver

Dudnichenko O, Penkov K, McKean M, Mandalà M, Kukushkina M, Panella T, et al. First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study. European Journal of Cancer. 2024;213:115070. doi:10.1016/j.ejca.2024.115070

BibTeX
@article{Dudnichenko2024,
  author = {Dudnichenko, Oleksandr and Penkov, Konstantin and McKean, Meredith and Mandalà, Mario and Kukushkina, Mariia and Panella, Timothy and Csőszi, Tibor and Gerletti, Paola and Thakur, Mahgull and Polli, Anna and di Pietro, Alessandra and Schadendorf, Dirk},
  title = {First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {213},
  pages = {115070},
  doi = {10.1016/j.ejca.2024.115070}
}
Kostenlos starten →